Revive Therapeutics Ltd.
- Country
- ๐จ๐ฆCanada
- Ownership
- Public
- Established
- 2012-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.revivethera.com
Clinical Trials
3
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)โข Click on a phase to view related trials
Bucillamine in Treatment of Patients With COVID-19
- First Posted Date
- 2020-08-07
- Last Posted Date
- 2023-07-07
- Lead Sponsor
- Revive Therapeutics, Ltd.
- Target Recruit Count
- 713
- Registration Number
- NCT04504734
- Locations
- ๐บ๐ธ
Cullman Clinical Trials, Cullman, Alabama, United States
๐บ๐ธAvant Research Associates, LLC, Huntsville, Alabama, United States
๐บ๐ธWest Valley Research Clinic, Phoenix, Arizona, United States
Bucillamine Phase 2 Trial in Patients With Cystinuria
- First Posted Date
- 2016-10-24
- Last Posted Date
- 2017-05-18
- Lead Sponsor
- Revive Therapeutics, Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT02942420
- Locations
- ๐บ๐ธ
University of Alabama - Department of Urology, Birmingham, Alabama, United States
๐บ๐ธMassachusette General Hospital, Boston, Massachusetts, United States
๐บ๐ธNew York University School of Medicine, New York, New York, United States
Bucillamine for the Treatment of Acute Gout Flare in Subjects With Moderate to Severe Gout
- First Posted Date
- 2015-01-05
- Last Posted Date
- 2016-10-05
- Lead Sponsor
- Revive Therapeutics, Ltd.
- Target Recruit Count
- 66
- Registration Number
- NCT02330796
- Locations
- ๐บ๐ธ
West Coast Research, San Roman, California, United States
๐บ๐ธTexas Physicians Research Medical Group, Arlington, Texas, United States
๐บ๐ธSun Research Institute, San Antonio, Texas, United States